VivoSim Labs (VIVS) appoints Tony Lialin as Chief Commercial Officer

VivoSim Labs, Inc. appointed Tony Lialin as Chief Commercial Officer effective August 11, 2025.

Rhea-AI Filing Summary

VivoSim Labs, Inc. appointed Tony Lialin as Chief Commercial Officer effective August 11, 2025. Mr. Lialin brings more than two decades of commercial experience in life sciences and will lead the company’s go-to-market strategy, partnerships, and expansion of San Diego services that combine organ-specific 3D models with AI-driven analytics. His initial annualized salary is $360,000 with a $10,000 sign-on bonus and eligibility for a performance bonus with a target up to 40% of base salary. The company granted a 40,000-share option under its 2022 Equity Incentive Plan vesting over four years (25% after one year, then quarterly thereafter). The Offer Letter and a press release are filed as Exhibits 10.1 and 99.1, respectively. Employment is at-will and no related-party or family relationships were reported.

Positive

• Experienced commercial hire: Tony Lialin brings more than two decades of life sciences commercial experience to lead go-to-market and partnerships.
• Aligned compensation package: Initial annualized salary of $360,000 with a $10,000 sign-on bonus and target incentive up to 40% of base salary.
• Equity incentive granted: Option to purchase 40,000 common shares under the 2022 Equity Incentive Plan, vesting over four years (25% at one year, then quarterly).
• Clear disclosure and exhibits: Offer Letter filed as Exhibit 10.1 and press release furnished as Exhibit 99.1.

Negative

• None.

Insights

Financial Analyst

TL;DR: Appointment strengthens commercial leadership with incentive-aligned compensation and equity to support go-to-market execution.

Mr. Lialin’s hiring provides VivoSim with a senior commercial executive who has built teams and partnerships in life sciences. The explicit compensation package—$360,000 base, $10,000 sign-on, target bonus up to 40%, and a 40,000-share option vesting over four years—aligns near-term and multi-year incentives toward revenue growth and partnership development. For investors, these are operational actions intended to accelerate commercialization of the company’s organ-specific 3D models and AI analytics services. The filing includes Offer Letter and press release exhibits for further detail.

Corporate Governance Expert

TL;DR: Disclosure is standard and complete for an officer appointment; no related-party concerns disclosed.

The Form 8-K outlines the appointment terms, equity award, at-will status, and an indemnity agreement. The company states there are no transactions reportable under Item 404 and no family relationships with other executives or directors, which addresses common governance flags. Exhibits include the Offer Letter (10.1) and press release (99.1). From a governance disclosure perspective, the filing meets routine requirements and does not raise immediate compliance issues based on the provided text.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is VivoSim Labs (VIVS) announcing in this 8-K?

The 8-K discloses the appointment of Tony Lialin as Chief Commercial Officer effective August 11, 2025 and related compensation and equity terms.

What are Tony Lialin’s compensation and incentives at VIVS?

His initial annualized salary is $360,000, he received a $10,000 sign-on bonus, and is eligible for a performance bonus with a target up to 40% of base salary.

What equity did the company grant to the new CCO?

The company granted an option to purchase 40,000 shares of common stock under the Amended & Restated 2022 Equity Incentive Plan, vesting over four years (25% after one year, then quarterly).

When did the appointment become effective and where is it disclosed?

The appointment was effective August 11, 2025 and is disclosed in this Current Report on Form 8-K with the Offer Letter filed as Exhibit 10.1 and a press release as Exhibit 99.1.

Are there any related-party transactions or family relationships disclosed?

No. The filing states there are no transactions reportable under Item 404 and no family relationships between Mr. Lialin and any director or executive officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 08:06 AM Learn about SEC filing dates

0001497253false00014972532025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

VivoSim Labs, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35996	27-1488943
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
11555 Sorrento Valley Rd Suite 100
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 224-1000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		VIVS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 7, 2025, the Board of Directors (the “Board”) of VivoSim Labs, Inc. (the “Company”) appointed Tony Lialin, age 54, as the Company’s Chief Commercial Officer, effective as of August 11, 2025.

Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. Prior to joining the Company, Mr. Lialin had served as Chief Commercial Officer of DPBIO. From April 2025 to June 2025, he served as Vice President Business Development of Seonix Bio and from April 2022 to April 2024, he served as Vice President Sales & Consumer Success of ONI. From March 2020 to April 2022, Mr. Lialin served as Chief Commercial Officer of Invivoscribe, Inc. At the Company, he will lead go-to-market strategy, partnerships, and the expansion of the company’s San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development.

In connection with his appointment, on July 25, 2025, Mr. Lialin and the Company entered into an offer letter (the “Offer Letter”). Pursuant to the Offer Letter, Mr. Lialin’s initial annualized salary is $360,000 and he received a sign-on bonus of $10,000. Additionally, Mr. Lialin will be eligible to participate in the Company’s bonus plan with a target incentive of up to 40% of his base salary. His salary and performance bonus percentage may be increased in the future at the discretion of the Compensation Committee of the Board. Mr. Lianlin’s employment is on an “at-will” basis.

In connection with his appointment, and as provided in the Offer Letter, on August 11, 2025, the Company granted Mr. Lialin an option pursuant to its Amended & Restated 2022 Equity Incentive Plan to purchase 40,000 shares of the Company’s common stock (the “Option”), which option will vest over four years, with 25% of the total number of shares subject to the Option vesting on August 11, 2026 and the balance vesting in 12 equal quarterly

installments thereafter, subject to Mr. Lialin’s continued service to the Company on each applicable vesting date.

The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

There are no transactions between Mr. Lialin and the Company that would be reportable under Item 404(a) of Regulation S-K. There also are no family relationships between Mr. Lialin and any director or executive officer of the Company. Mr. Lialin was not selected to serve as the Company’s Chief Commercial Officer pursuant to any arrangement or understanding with any person. The Company has also entered into the Company’s standard form Indemnity Agreement with Mr. Lialin.

Item 7.01 Regulation FD Disclosure.

On August 14, 2025, the Company issued a press release announcing that it has appointed Tony Lialin as its Chief Commercial Officer. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
10.1		Offer Letter, dated July 25, 2025, between VivoSim Labs, Inc. and Tony Lialin.
99.1		Press Release dated August 14, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			VivoSim Labs, Inc.
Date:	August 14, 2025	By:	/s/ Keith Murphy
			Name: Keith Murphy Title: Executive Chairman